Alnylam and Inceptive launch up to $2B AI alliance to accelerate RNAi drug discovery, integrating siRNA expertise with foundation models.
Written By: Samiksha Jadhav, BPharm
Reviewed By: Pharmacally Editorial Team
Alnylam Pharmaceuticals has entered a collaboration worth up to $2 billion with Inceptive Nucleics to apply generative artificial intelligence to the discovery and optimization of RNA interference (RNAi) therapeutics.
The agreement includes $30 million in upfront consideration, split between cash and an equity investment in Inceptive. Inceptive will also be eligible for additional preclinical, regulatory, and commercial milestone payments tied to the advancement of collaboration programs.
RNAi Platform Meets AI Models
Alnylam, a pioneer of RNAi therapeutics, has developed six approved medicines across multiple disease areas and built one of the industry’s largest proprietary siRNA datasets over more than two decades. The partnership integrates this data with Inceptive’s AI foundation models, which are trained to recognize biological patterns across sequence-based medicines.
In joint exploratory studies, Inceptive’s models achieved strong performance within weeks, identifying biologically relevant patterns from relatively small datasets and rapidly characterizing siRNA molecules. The findings support the potential of foundation models to accelerate the design of RNA-based therapeutics and uncover insights that may be difficult to identify through conventional approaches.
Expanding Therapeutic Design Space
The collaboration will apply AI to analyze target messenger RNA (mRNA) sequences, explore novel siRNA designs, and evaluate chemical modifications, including sugar, backbone, and conjugate chemistries that influence potency, stability, and tissue delivery. The partners will also use the models to predict high-performing therapeutic candidates before preclinical testing.
By improving candidate selection earlier in development, the alliance could reduce experimental burden, increase research productivity, and shorten discovery timelines. The effort reflects a broader industry shift toward integrating advanced AI systems to improve decision-making and reduce attrition across drug discovery programs.
Competitive Landscape
The alliance ranks among the largest AI-focused investments in nucleic acid drug discovery. Similar collaborations between Eli Lilly and Isomorphic Labs and between Bristol Myers Squibb and VantAI reflect growing industry confidence in foundation models as tools for therapeutic design and candidate optimization. Alnylam’s investment further highlights the strategic importance of AI in expanding the therapeutic potential of RNAi medicines.
Executive Perspective
Yvonne Greenstreet, MD, Chief Executive Officer of Alnylam, said the collaboration creates an opportunity to combine the company’s RNAi platform and scientific expertise with advanced AI capabilities to accelerate the development of new medicines. She described Inceptive as a leader at the intersection of artificial intelligence and biology, with a vision to transform how RNA medicines are designed.
Jakob Uszkoreit, co-founder and Chief Executive Officer of Inceptive, said traditional drug discovery often relies on extensive trial-and-error experimentation. He noted that Inceptive’s foundation models are built to learn the complex biological rules underlying therapeutic design, enabling researchers to identify promising candidates more efficiently.
Path Forward
The collaboration supports Alnylam’s Alnylam 2030 strategy, which calls for significant pipeline expansion through platform innovation. In addition to gaining access to Inceptive’s AI technology, Alnylam will work closely with the company’s scientific leadership, including Uszkoreit, a co-inventor of the Transformer architecture that underpins modern generative AI systems.
By combining a validated RNAi development engine with advanced foundation models, the partnership could help identify higher-quality therapeutic candidates earlier in discovery and accelerate their progression toward preclinical development, strengthening Alnylam’s position at the intersection of RNA biology and artificial intelligence.
References
About the Writer
Samiksha Vikram Jadhav (LinkedIn) is a B. Pharm graduate with a strong academic foundation in pharmaceutical sciences, pharmacology, and drug development. She specializes in pharma market research, with a focused interest in mergers and acquisitions, strategic partnerships, and global pharma and biotech deals. Her work centers on analyzing industry transactions, market positioning, and business strategies, translating complex developments into clear, accurate, and insightful scientific and commercial reporting.
